HomeCompareNVTA vs ARCC

NVTA vs ARCC: Dividend Comparison 2026

NVTA yields 10526.32% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVTA wins by $91421458538285344.00M in total portfolio value
10 years
NVTA
NVTA
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91421458538285344.00M
Annual income
$89,744,322,218,307,970,000,000.00
Full NVTA calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — NVTA vs ARCC

📍 NVTA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVTAARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVTA + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVTA pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVTA
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$76,282,673,885,561,770,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, NVTA beats the other by $76,282,673,885,561,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVTA + ARCC for your $10,000?

NVTA: 50%ARCC: 50%
100% ARCC50/50100% NVTA
Portfolio after 10yr
$45710729269142672.00M
Annual income
$44,872,161,109,153,986,000,000.00/yr
Blended yield
98.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

NVTA
Analyst Ratings
4
Buy
6
Hold
5
Sell
Consensus: Hold
Price Target
$9.75
+51215.8% upside vs current
Range: $2.25 — $17.00
Altman Z
-23.1
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVTA buys
0
ARCC buys
0
No recent congressional trades found for NVTA or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVTAARCC
Forward yield10526.32%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$91421458538285344.00M$24.5K
Annual income after 10y$89,744,322,218,307,970,000,000.00$1.16
Total dividends collected$91309952364754128.00M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$9.75$21.88

Year-by-year: NVTA vs ARCC ($10,000, DRIP)

YearNVTA PortfolioNVTA Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$1,063,332$1,052,631.58$11,381$541.15+$1.05MNVTA
2$105,744,905$104,607,140.08$12,621$284.08+$105.73MNVTA
3$9,835,430,757$9,722,283,708.79$13,827$145.31+$9835.42MNVTA
4$855,644,041,989$845,120,131,078.84$15,062$73.43+$855644.03MNVTA
5$69,627,827,846,009$68,712,288,721,080.95$16,364$36.89+$69627827.83MNVTA
6$5,300,152,192,813,391$5,225,650,417,018,161.00$17,757$18.49+$5300152192.80MNVTA
7$377,430,657,448,967,200$371,759,494,602,656,830.00$19,258$9.25+$377430657448.95MNVTA
8$25,145,413,383,015,215,000$24,741,562,579,544,820,000.00$20,880$4.63+$25145413383015.20MNVTA
9$1,567,417,121,474,185,500,000$1,540,511,529,154,359,300,000.00$22,636$2.32+$1567417121474185.50MNVTA
10$91,421,458,538,285,340,000,000$89,744,322,218,307,970,000,000.00$24,539$1.16+$91421458538285344.00MNVTA

NVTA vs ARCC: Complete Analysis 2026

NVTAStock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Full NVTA Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this NVTA vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVTA vs SCHDNVTA vs JEPINVTA vs ONVTA vs KONVTA vs MAINNVTA vs HTGCNVTA vs GBDCNVTA vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.